ASCO24 Updates: Delphine Chen on Radiopharmaceutical Imaging and Therapy Innovations / ASCO, ASCO24, ASCO24 updates, cancer, Delphine Chen, OncoDaily, Oncology

The Alberta government has announced a $71 million investment to build a new radiopharmaceutical centre in Calgary. The project, a collaboration between the province and local partners, aims to addres… · Photo : US Army Africa · CC BY · Flickr

TEHRAN (Tasnim) – A research center of the Atomic Energy Organization of Iran (AEOI) has produced a radiopharmaceutical used for the treatment of cancerous tumors.

Machine learning is reshaping radiopharmaceutical cancer therapy. According to @JMIR, AI algorithms accelerate drug discovery … #Artificialintelligence #Drugdiscovery #Machinelearning #Oncology #Personalizeddosimetry

Global Radiopharmaceutical Nuclear Medicine Market valued at USD 5.8 Bn in 2025, projected to reach USD 9.1 Bn by 2034, CAGR 4.7% forecast period.

Recent patents relating to radiopharmaceutical compositions, preparation methods and delivery systems.

Radiopharmaceutical publicly funded in some provinces has fewer side effects than chemotherapy and can increase survival by about half a year

As cancer treatments advance, the ability to create radioisotopes is being expanded to Calgary — reducing transport barriers and bringing life-saving care closer to patients.

Background: Our research group previously developed a virtual reality (VR) training module for radiopharmaceutical administration, focusing on procedural skills and patient interactions. The module’s educational effectiveness was validated with objective measures, such as electroencephalography and mood assessments. Objective: The authors aimed to extend the module by integrating a radiation visualization system that renders otherwise invisible radiation fields within an immersive VR environment, and to compare students’ learning experiences associated with the module with those associated with conventional hands-on training. Methods: Twenty students enrolled in a radiological technician training program participated in this study. Students’ learning experiences were evaluated using Likert-scale–based questionnaires, together with qualitative analysis of open-ended responses. Results: VR-based training was associated with significantly higher ratings for students’ conceptual understanding of radiation behavior, radiation safety awareness, learning satisfaction, and self-assessed competency than conventional training. Conversely, perceived realism and immersion were rated significantly higher following conventional training. No significant differences were observed for operational understanding, technical skills, or system usability. Conclusions: These findings suggest that the developed VR module offers a safe and repeatable training platform that may support positively perceived learning experiences in radiopharmaceutical administration and radiation safety education.

"Domestic radiopharmaceutical suppliers, who receive isotopes from abroad, would be impacted by price changes and uncertainty caused by additional tariffs,” SNMMI President Cathy Cutler, PhD, wrote in...

Raw material dependency and transport bottlenecks, not just production capacity, are the key challenges facing the EU's radiopharmaceutical sector, according to the European Medicines Agency (EMA).

The application of Au(I) ions in pharmaceuticals, including in nuclear medicine, is limited by their instability towards reduction in vivo. The gold radionuclide 198Au with a half-life of 2.7 days emi...

XenoSTART and Minerva Imaging Create PDX-Radiopharmaceutical Oncology Drug Development Platform / cancer, Michael Wick, Minerva Imaging, Nick Slack,

The Alberta government, the Alberta Cancer Foundation and partners announced $71 million in funding to complete the upcoming Calgary Radiopharmaceutical Centre. Read More

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is proud to announce the launch of the Global Radiopharmaceutical Trial Finder a revolutionary, AI-powered platform designed to help resea...

RayzeBio gets global rights to radiopharmaceutical OncoACP3, which targets prostate cancer

Targeted alpha therapies could better attack tumors while reducing damage to healthy tissue.